Stock Performance Spotlight: Cellebrite DI Ltd (CLBT) Ends the Day at $15.87, Up by 0.32

Kiel Thompson

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

As of close of business last night, Cellebrite DI Ltd’s stock clocked out at $15.87, up 0.32% from its previous closing price of $15.82. In other words, the price has increased by $0.32 from its previous closing price. On the day, 1.04 million shares were traded. CLBT stock price reached its highest trading level at $15.97 during the session, while it also had its lowest trading level at $15.7.

Ratios:

To gain a deeper understanding of CLBT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 27.10. For the most recent quarter (mrq), Quick Ratio is recorded 2.05 and its Current Ratio is at 2.08. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.

Upgrades & Downgrades

In the most recent recommendation for this company, Needham on March 28, 2024, Reiterated its Buy rating but revised its target price to $13.50 from $13 previously.

BofA Securities Upgraded its Neutral to Buy on February 16, 2024, whereas the target price for the stock was revised from $9 to $12.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’25 when SHAPIRA AYALA BERLER bought 8,448 shares for $18.05 per share.

DAVID GEE bought 1,969 shares of CLBT for $33,237 on Nov 24 ’25. On Nov 21 ’25, another insider, DAVID GEE, who serves as the OFFICER of the company, bought 3,704 shares for $17.44 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLBT now has a Market Capitalization of 3879724544 and an Enterprise Value of 3360211712. As of this moment, Cellebrite’s Price-to-Earnings (P/E) ratio for their current fiscal year is 51.73, and their Forward P/E ratio for the next fiscal year is 40.16. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.34 while its Price-to-Book (P/B) ratio in mrq is 8.49. Its current Enterprise Value per Revenue stands at 7.37 whereas that against EBITDA is 46.634.

Stock Price History:

The Beta on a monthly basis for CLBT is 1.28, which has changed by -0.31 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, CLBT has reached a high of $26.30, while it has fallen to a 52-week low of $13.10. The 50-Day Moving Average of the stock is -10.96%, while the 200-Day Moving Average is calculated to be -7.41%.

Shares Statistics:

It appears that CLBT traded 1.21M shares on average per day over the past three months and 1414580 shares per day over the past ten days. A total of 239.47M shares are outstanding, with a floating share count of 114.18M. Insiders hold about 52.32% of the company’s shares, while institutions hold 46.80% stake in the company. Shares short for CLBT as of 1767139200 were 5828954 with a Short Ratio of 4.81, compared to 1764288000 on 5227810. Therefore, it implies a Short% of Shares Outstanding of 5828954 and a Short% of Float of 4.8299997999999995.

Earnings Estimates

A detailed examination of Cellebrite DI Ltd (CLBT) is currently in progress, with 8.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.11, with high estimates of $0.13 and low estimates of $0.09.

Analysts are recommending an EPS of between $0.54 and $0.47 for the fiscal current year, implying an average EPS of $0.51. EPS for the following year is $0.55, with 8.0 analysts recommending between $0.61 and $0.46.

Revenue Estimates

In. The current quarter, 8 analysts expect revenue to total $126.07M. It ranges from a high estimate of $128M to a low estimate of $123.17M. The current estimate, Cellebrite DI Ltd’s year-ago sales were $109.05MFor the next quarter, 8 analysts are estimating revenue of $125.2M. There is a high estimate of $128M for the next quarter, whereas the lowest estimate is $121.87M.

A total of 8 analysts have provided revenue estimates for CLBT’s current fiscal year. The highest revenue estimate was $475M, while the lowest revenue estimate was $470.03M, resulting in an average revenue estimate of $472.92M. In the same quarter a year ago, actual revenue was $401.2MBased on 8 analysts’ estimates, the company’s revenue will be $554.5M in the next fiscal year. The high estimate is $569.1M and the low estimate is $540M.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.